Grünenthal's proprietary NaV 1.8 inhibitor enters clinical development
PR Newswire —
AACHEN, Germany, Feb. 18, 2026 /PRNewswire/ -- Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy...